Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
囊泡 肿瘤
/
PI3K/Akt/mTOR
帕金森与阿尔茨海默症 肿瘤生长增殖和凋亡 PPARs
/ Akt / AKT inhibitor VIII

AKT inhibitor VIII {[allProObj[0].p_purity_real_show]}

货号：A314665 同义名： AKTi-1/2

Akt inhibitor VIII is a allosterical and isozyme-selective Akt inhibitor with IC50 value of 58 nM, 210 nM, and 2.12 μM for Akt1, Akt2, and Akt3.

AKT inhibitor VIII 化学结构 CAS号：612847-09-3
AKT inhibitor VIII 化学结构
CAS号：612847-09-3
AKT inhibitor VIII 3D分子结构
CAS号：612847-09-3
AKT inhibitor VIII 化学结构 CAS号：612847-09-3
AKT inhibitor VIII 3D分子结构 CAS号：612847-09-3
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

AKT inhibitor VIII 纯度/质量文件 产品仅供科研

货号：A314665 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
• JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
• BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
• J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
• PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >
产品名称 Akt ↓ Akt1 ↓ Akt2 ↓ Akt3 ↓ 其他靶点 纯度
Honokiol ✔ MEK 98%
PF-04691502 ++++

P-Akt (S473), IC50: 3.8 nM

P-Akt (T308), IC50: 7.5 nM

 		98+%
PHT-427 +

Akt, Ki: 2.7 μM

 		99%+
Deguelin ✔ PI3K 99%+
TIC10 isomer ✔ ERK 98+%
Perifosine +

Akt, IC50: 4.7 μM

 		98%
Miltefosine ✔ PI3K,PKC 98%
Triciribine +

Akt, IC50: 130 nM

 		99%+
Uprosertib +

Akt1, IC50: 180 nM

 		+

Akt2, IC50: 328 nM

 		++

Akt3, IC50: 38 nM

 		99%+
Afuresertib ++++

Akt1, Ki: 0.08 nM

 		++++

Akt2, Ki: 2 nM

 		++++

Akt3, Ki: 2.6 nM

 		99%+
Miransertib ++++

Akt1, IC50: 5 nM

 		++++

Akt2, IC50: 4.5 nM

 		++

Akt3, IC50: 16 nM

 		98+%
GSK-690693 ++++

Akt1, IC50: 2 nM

 		+++

Akt2, IC50: 13 nM

 		+++

Akt3, IC50: 9 nM

 		99%+
AT7867 ++

Akt1, IC50: 32 nM

 		++

Akt2, IC50: 17 nM

 		++

Akt3, IC50: 47 nM

 		PKA 99%+
AKT inhibitor VIII ++

Akt1, IC50: 58 nM

 		+

Akt2, IC50: 210 nM

 		+

Akt3, IC50: 2119 nM

 		98+%
MK-2206 2HCl +++

Akt1, IC50: 8 nM

 		+++

Akt2, IC50: 12 nM

 		+

Akt3, IC50: 65 nM

 		99%+
Ipatasertib ++++

Akt1, IC50: 5 nM

 		++

Akt2, IC50: 18 nM

 		+++

Akt3, IC50: 8 nM

 		99%+
AT13148 ++

Akt1, IC50: 38 nM

 		+

Akt2, IC50: 402 nM

 		++

Akt3, IC50: 50 nM

 		PKA 98+%
Capivasertib ++++

Akt1, IC50: 3 nM

 		+++

Akt2, IC50: 8 nM

 		+++

Akt3, IC50: 8 nM

 		99%+
A-674563 HCl +++

Akt1, Ki: 11 nM

 		PKA 98%
CCT128930 +++

Akt2, IC50: 6 nM

 		PKA 98+%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

AKT inhibitor VIII 生物活性

靶点

  • Akt3

    Akt3, IC50:2119 nM

  • Akt1

    Akt1, IC50:58 nM

  • Akt2

    Akt2, IC50:210 nM
描述 Akt/PKB (protein kinase B) is a serine/threonine kinase which has a key role in the regulation of survival and proliferation. There are three isoforms of human Akt (Akt1, Akt2 and Akt3) and they all have an N-terminal PH (pleckstrin homology) domain and a kinase domain separated by a 39-amino-acid hinge region[3]. AKT inhibitor VIII（Akti-1/2), a cell-permeable quinoxaline compound, is an non-ATP-competitive inhibitor with IC50s of 58 nM, 210 nM, and 2119 nM towards Akt1, Akt2, and Akt3, respectively[4]. This inhibitor prevents phosphorylation of PKB isoforms(Akt1, Akt2 and Akt3), possibly by interfering with the PH domain and/or hinge region of PKB. In vivo study, it was showed that Akti-1/2 can completely inhibit thrombin-mediated phosphorylation of PKB and its downstream substrate GSK3β at a concentration of 5 μM[5]. Akti-1/2 treatment induced an increase in NOXA protein levels and a down-regulation of the levels of MCL-1, a critical survival protein in chronic lymphocytic leukemia (CLL) cells, which indicated that Akti-1/2 might be a new therapeutic option for the treatment of CLL[6].

AKT inhibitor VIII 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
184B5 cells 20 μM Cytotoxicity assay Cytotoxicity against human 184B5 cells at 20 uM chloroquine by SRB assay, GI50=25.76 μM 18691894
22RV1 cell Growth inhibition assay Inhibition of human 22RV1 cell growth in a cell viability assay, IC50=6.61424 μM SANGER
23132-87 cell Growth inhibition assay Inhibition of human 23132-87 cell growth in a cell viability assay, IC50=0.75938 μM SANGER
639-V cell Growth inhibition assay Inhibition of human 639-V cell growth in a cell viability assay, IC50=5.8773 μM SANGER

AKT inhibitor VIII 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01257594 Brain Cancer Not Applicable Unknown December 2016 United States, New Jersey ... 展开 >> Memorial Sloan-Kettering at Basking Ridge Basking Ridge, New Jersey, United States, 07920 United States, New York Memorial Sloan-Kettering Cancer Center at Commack Commack, New York, United States, 11725 Columbia University Medical Center New York, New York, United States, 10032 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00897663 - Completed - United States, Arizona ... 展开 >> Mayo Clinic Scottsdale Scottsdale, Arizona, United States, 85259-5499 United States, Florida Mayo Clinic - Jacksonville Jacksonville, Florida, United States, 32224 United States, Iowa Siouxland Hematology-Oncology Associates, LLP Sioux City, Iowa, United States, 51101 Mercy Medical Center - Sioux City Sioux City, Iowa, United States, 51102 St. Luke's Regional Medical Center Sioux City, Iowa, United States, 51104 United States, Minnesota Mayo Clinic Cancer Center Rochester, Minnesota, United States, 55905 United States, North Dakota Medcenter One Hospital Cancer Care Center Bismarck, North Dakota, United States, 58501 Mid Dakota Clinic, PC Bismarck, North Dakota, United States, 58501 St. Alexius Medical Center Cancer Center Bismarck, North Dakota, United States, 58502 United States, South Dakota Rapid City Regional Hospital Rapid City, South Dakota, United States, 57701 收起 <<

AKT inhibitor VIII 参考文献

[1]Logie L, Ruiz-Alcaraz AJ, et al. Characterization of a protein kinase B inhibitor in vitro and in insulin-treated liver cells. Diabetes. 2007 Sep;56(9):2218-27.

[2]Lindsley CW, Zhao Z, et al. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):761-4.

[3]Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, Jones RE, Kahana JA, Kral AM, Leander K, Lee LL, Malinowski J, McAvoy EM, Nahas DD, Robinson RG, Huber HE. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J. 2005 Jan 15;385(Pt 2):399-408. doi: 10.1042/BJ20041140. PMID: 15456405; PMCID: PMC1134710.

[4]Lindsley CW, Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huff JR, Huber HE, Duggan ME. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):761-4. doi: 10.1016/j.bmcl.2004.11.011. PMID: 15664853.

[5]Hunter RW, Harper MT, Hers I. The PKB inhibitor Akti-1/2 potentiates PAR-1-mediated platelet function independently of its ability to block PKB. J Thromb Haemost. 2008 Nov;6(11):1923-32. doi: 10.1111/j.1538-7836.2008.03140.x. Epub 2008 Aug 28. PMID: 18761726.

[6]de Frias M, Iglesias-Serret D, Cosialls AM, Coll-Mulet L, Santidrián AF, González-Gironès DM, de la Banda E, Pons G, Gil J. Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Haematologica. 2009 Dec;94(12):1698-707. doi: 10.3324/haematol.2008.004028. Epub 2009 Oct 8. PMID: 19815839; PMCID: PMC2791940.

AKT inhibitor VIII 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.81mL

0.36mL

0.18mL

9.06mL

1.81mL

0.91mL

18.13mL

3.63mL

1.81mL

AKT inhibitor VIII 技术信息

CAS号612847-09-3
分子式C34H29N7O
分子量 551.64
别名 AKTi-1/2
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Sealed in dry,Store in freezer, under -20°C
溶解度

DMSO: 18 mg/mL(32.63 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方

Tags: AKT inhibitor VIII | 612847-09-3 | AKTi-1/2 | Akt | AKT Inhibitor | PI3K/Akt/mTOR | Apoptosis | Akt | Apoptosis | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | AKT inhibitor VIII 纯度/质量文件 | AKT inhibitor VIII 亚型比较 | AKT inhibitor VIII 生物活性 | AKT inhibitor VIII 细胞研究 | AKT inhibitor VIII 临床数据 | AKT inhibitor VIII 参考文献 | AKT inhibitor VIII 实验方案 | AKT inhibitor VIII 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z